The Effect of Cooling on Sclerotherapy Efficacy

NCT ID: NCT04690803

Last Updated: 2021-01-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-01-06

Study Completion Date

2022-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to evaluate the efficacy of sclerotherapy with forced-air cooling during treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study Objective: The primary objective of this study is to evaluate the efficacy of sclerotherapy with forced-air cooling during treatment.

Study Design: This will be an investigator-initiated, evaluator-blinded, randomized-controlled, prospective, single-center clinical trial.

Study Population: 20 evaluable subjects with bilateral lower extremity reticular and telangiectatic veins, who meet all study inclusion/exclusion criteria will be considered for entry into the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Leg Veins

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

sclerotherapy with forced-air cooling during treatment.
Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Investigators
evaluator-blinded

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

treatment with forced-air cooling

comparing treatment with and without forced-air cooling in a comparative lower extremity model

Group Type ACTIVE_COMPARATOR

air cooling

Intervention Type DRUG

intervention is adding air-cooling to treatment

treatment without forced-air cooling

comparing treatment without forced-air cooling in a comparative lower extremity model

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

air cooling

intervention is adding air-cooling to treatment

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The subject is a male or female of skin type I to IV between 25 and 75 years of age.
* The subject has mild venous disease (CEAP Class C1) (CLINICAL SEVERITY ETIOLOGY OR CAUSE ANATOMY AND PATHOPHYSIOLOGY)
* Reticular veins and telangiectasias on symmetrical bilateral lower extremities.
* The subject is willing to follow study instructions and complete all required visits, as well as has agreed to and signed the written informed consent form.
* The subject is healthy as judged by medical history and investigator's assessment of current health.
* The subject is not suffering from any skin condition (infection, dermatosis, etc.) that in the opinion of the investigator may place them at risk.
* Females of childbearing potential must use one of the following types of birth control for the duration of the study. These include: Oral contraceptives, contraceptive patches/rings/implants, Implanon®, Depo-Provera®, double-barrier methods (e.g. condoms with spermicide), abstinence, or partner vasectomy, with a documented second acceptable method of birth control should they become sexually active. All birth control measures must be in consistent use for at least 30 days prior to the start of study.

Exclusion Criteria

* A subject requires greater than 10 mL total of glycerin, including a maximum of 6 mL of polidocanol for foam sclerotherapy, for either lower extremity during a single leg treatment.
* Asymmetric amount, distribution, and/or severity of reticular veins and/or telangiectasias between lower extremities
* The subject has a CEAP Class of C2 or greater, as evidenced by clinically apparent varicosities, venous stasis, stasis dermatitis, lipodermatosclerosis, and/or venous ulceration (or history of lower leg ulcerations).
* The subject has history of or current great saphenous vein (GSV), saphenofemoral junction (SFJ), or saphenopopliteal junction (SPJ) incompetency based on prior Doppler and/or duplex evaluation or has physical exam findings suspicious for it.
* The subject has a history of deep vein thrombosis, thrombophlebitis, thromboembolic disease, and/or underlying hypercoagulable medical condition (e.g. hemophilia, Factor V deficiency).
* The subject has a history of uncontrolled or severe asthma, or asthma requiring hospitalization or intubation.
* The subject has a history of allergic reactions to sclerosing agent.
* The subject has a history of allergic reaction or sensitivity to lidocaine or epinephrine.
* Any of the following medications, procedures or treatments to the purposed treatment area/s

1. Within 6 months prior to screening visit (i.) The subject has undergone sclerotherapy
2. Within 3 months prior to screening visit (I.) NO OTHER COSMETIC OR SURGICAL TREATMENTS TO THE PURPOSED TREATMENT AREA/S
* The subject is non-ambulatory or poorly ambulatory.
* The subject has a history of neurological conditions.
* The subject is pregnant, lactating, or in child bearing age (and sexually active) and not using an approved contraceptive measure.
* The subject is taking disulfiram, tamoxifen, or oral hormone therapy (not including hormonal birth control).
* The subject has a history of noncompliance with clinical protocols.
* The subject has participated in any other clinical trial that involves an investigational medication or device within the last 30 days.
* Planning to have any treatments or procedures to bilateral lower extremities for the duration of the trial.
Minimum Eligible Age

25 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Goldman, Butterwick, Fitzpatrick and Groff

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

West Dermatology Research Center/Cosmetic Laser Dermatology

San Diego, California, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Leslie Aguilar, BA

Role: CONTACT

18586571004

Sherif Mikhail

Role: CONTACT

8586571004

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Leslie Aguilar, BA

Role: primary

858-657-1004

Sherif Mikhail, MD

Role: backup

8586571004

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ScleroTT2019-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Venous Compression in Fontan
NCT07220226 NOT_YET_RECRUITING NA